- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004825
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism.
II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population.
III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE: Octreotide and/or diazoxide are discontinued on day 1, and fasting blood glucose is monitored. Patients receive test meals of Sustacal on days 3 and 4 and are assessed for insulin response.
Beginning on day 5, patients are given recombinant human insulin-like growth factor I subcutaneously every 12 hours for a total of 3 doses. The first dose (on day 5) is given 30 minutes before a Sustacal challenge, the second dose is followed by a bedtime snack, and the third dose (on day 6) is followed by a supervised fast.
Study Type
Enrollment
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of hyperinsulinism (i.e. evidence of fasting hypoglycemia with inadequate suppression of insulin, normal pituitary and adrenal function, and increased insulin action)
Suboptimal control of blood sugar (i.e. inability to fast at least 10 hours with a blood sugar of 60 mg/dL or greater)
No suspected insulinoma
Must be currently managed on a regimen of diazoxide, octreotide and/or frequent feedings to control hypoglycemia
--Prior/Concurrent Therapy--
See Disease Characteristics
--Patient Characteristics--
Hematopoietic: No anemia or other concerns of blood volume depletion
Renal: No renal dysfunction
Other:
- No known malignancy
- No other major medical conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Pinchas Cohen, Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/13283
- CHP-FDR001181-ST
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperinsulinism
-
University of Castilla-La ManchaEnrolling by invitationGlucose, High Blood | Exercise-Induced HyperinsulinismSpain
-
University Hospital, Basel, SwitzerlandGottfried und Julia Bangerter-Rhyner-StiftungRecruitingEndogenous HyperinsulinismSwitzerland
-
University Medicine GreifswaldCompletedNon-focal Congenital HyperinsulinismGermany
-
Elizabeth A RosenfeldNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedHyperinsulinism-Hyperammonemia SyndromeUnited States
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; Lawson Wilkins Pediatric Endocrine SocietyWithdrawn
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedPersistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) | Congenital Hyperinsulinism (CHI)United States
-
Miguel PampaloniRecruitingCongenital HyperinsulinismUnited States
-
Zealand PharmaCompletedCongenital HyperinsulinismUnited States, United Kingdom, Germany, Israel
-
Montefiore Medical CenterNo longer availableCongenital HyperinsulinismUnited States
-
Diva De LeonTerminatedCongenital HyperinsulinismUnited States
Clinical Trials on recombinant human insulin-like growth factor I
-
Massachusetts General HospitalCompletedDisorder of Bone Density and Structure, UnspecifiedUnited States
-
Children's Hospital of PhiladelphiaCompleted
-
Beth Israel Deaconess Medical CenterCompletedHyperglycemia | Insulin ResistanceUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnMalignant Neoplasm | Gastrointestinal Mucositis
-
Children's Hospital of PhiladelphiaCompleted
-
Beijing Tongren HospitalRecruiting
-
Martin, PaulNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditionsUnited States
-
Bispebjerg HospitalThe Danish Medical Research CouncilUnknown
-
Daewoong Pharmaceutical Co. LTD.CompletedDiabetic Foot Ulcer Patients With Uncontrolled Diabetes MellitusKorea, Republic of
-
Wright State UniversityRecruitingAging | UVB Phototherapy Burn | Insulin-like Growth Factor 1United States